This is an external link. Click “OK” to continue.
Vice Chairman (retired) Mastercard Incorporated, USA
Formerly a senior executive in global banking, Walt is a director of numerous private, public, and charitable endeavors.
MBA Schulich School of Business, York University, Canada
Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.
“Better medicines for pain promise a better world for billions of people.”
Emeritus Professor, Pharmacology William Harvey Research Institute, Queen Mary University, UK
PhD Pharmacology University of London, UK
Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies.
“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”
|Former CFO Heron Therapeutics, USA
Director Public biotechnology companies
In his most recent role, Robert was CFO of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product.
|BBA St. Bonaventure University, USA
Robert is a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
“It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”
VP Business Development Knight Therapeutics, Canada
MBA University of Ottawa, Canada
Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M.
“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures.
JD Queen’s University, Canada
Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
VP Investor Relations and Strategy Calithera Biosciences, USA
Master of Health Administration (MHA) Cornell University, USA
Jennifer managed biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund.
“The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”
John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.)
PhD Medical Science University of Toronto, Canada
John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago.
“As research delivers new insights into the deep biology of hydrogen sulfide, we are widening our exploration of its therapeutic potential.”
CEO MaRS Discovery District, Canada
Entrepreneurial Masters Program Massachusetts Institute of Technology, USA
Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”.
“Antibe ranks amongst the most promising biotech companies that we work with.”
1. Audit Committee
2. Compensation Committee
3. Governance Committee